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Abstract
Background and purpose: To determine how the coverage of specialized allied health ser-
vices for patients with Parkinson's disease (PD) has developed in the Netherlands since 
the publication of trials that demonstrated cost-effectiveness.
Methods: We used healthcare expenditure-based data on all insured individuals in the 
Netherlands to determine the annual proportion of patients with PD who received ei-
ther specialized or generic allied health services (physiotherapy, occupational therapy, 
speech–language therapy) in 2 calendar years separated by a 5-year interval (2012 and 
2017). Specialized allied health services were delivered through the ParkinsonNet ap-
proach, which encompassed professional training and concentration of care among spe-
cifically trained professionals.
Results: Between 2012 and 2017, there was an increase in the number of patients with 
any physiotherapy (from 17,843 [62% of all patients with PD that year] to 22,282 [68%]), 
speech–language therapy (from 2171 [8%] to 3378 [10%]), and occupational therapy 
(from 2813 [10%] to 5939 [18%]). Among therapy-requiring patients, the percentage who 
were treated by a specialized therapist rose substantially for physiotherapy (from 36% 
in 2012 to 62% in 2017; χ2 = 2460.2; p < 0.001), speech–language therapy (from 59% 
to 85%; χ2 = 445.4; p < 0.001), and occupational therapy (from 61% to 77%; χ2 = 231.6; 
p < 0.001). By contrast, the number of patients with generic therapists did not change 
meaningfully. By 2017, specialized care delivery had extended to regions that had been 
poorly covered in 2012, essentially achieving nationwide coverage.
Conclusions: Following the publication of positive trials, specialized allied healthcare de-
livery was successfully scaled for patients with PD in the Netherlands, potentially serving 
as a template for other healthcare innovations for patients with PD elsewhere.
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INTRODUC TION
Parkinson's disease (PD) currently affects over 6 million individuals 
worldwide, posing an enormous burden on patients, relatives, and 
caregivers [1]. During the last 3 decades, the global burden of PD has 
more than doubled, in large part as a result of increasing numbers 
of older people, although environmental factors may contribute as 
well [1]. In the absence of preventive modalities for PD, the social 
and economic burden caused by PD is expected to rise further in the 
coming decades [2]. Against this background, there is an urgent need 
to widely implement treatment modalities that have been proven to 
be effective for patients with PD.
Recent years witnessed large gains in the nonpharmacological 
treatment of PD. In particular, several studies demonstrated that 
specialized care delivery of physiotherapy [3], occupational ther-
apy [4], and speech–language therapy [5] can lead to fewer com-
plications and to a better quality of life for patients with PD. The 
Dutch ParkinsonNet is an innovative model of integrated care that 
entails specialized care delivery across each of these disciplines 
[6,7]. To be considered specialized, allied therapists participating 
in ParkinsonNet must complete extensive and repeated training 
programs, comply with an annual performance review, and treat a 
minimum number of five patients with PD each year. Clinical stud-
ies suggest that since the introduction of this care model in the 
Netherlands in 2004, patients with PD sustain fewer disease com-
plications and experience an improvement in self-perceived per-
formance in daily activities, and healthcare costs have decreased 
[3,4,8,9]. These findings suggest that the future burden of PD at the 
population level could be reduced if delivery of such cost-effective 
specialized care could be implemented on a broader scale. However, 
it generally remains challenging to translate clinical trial findings into 
a sustainable implementation within everyday clinical practice.
Here, we investigate temporal trends between 2012 and 2017 in 
the coverage of specialized allied healthcare to patients with PD in 
the Netherlands, delivered through the ParkinsonNet approach, as 
a potential template for scaling of care delivery for patients with PD 
or other chronic conditions elsewhere.
METHODS
Data source
We retrospectively analyzed a database of health insurance claims 
(Vektis) that contains the healthcare expenditures of all insured in-
dividuals in the Netherlands, which is 99% of all Dutch residents 
(±17 million people). We used data from Vektis between 1 January 
2012 and 31 December 2017, as data on the number of patients with 
PD receiving specialized care before 2012 were incomplete for oc-
cupational therapy and speech–language therapy. We could not use 
data after 2017 because these data had not been fully processed 
when we conducted the current study.
We extracted data on community-based physiotherapy, occupa-
tional therapy, and speech–language therapy. Of note, this analysis 
does not include data on therapies provided in the setting of hos-
pitals or nursing homes. We used diagnostic codes obtained from 
medical records of all neurological departments in the Netherlands 
to identify patients with PD (Diagnosis Related Group code 501). We 
considered patients with PD who were referred to an allied health 
therapist to be therapy-requiring patients. Allocation to specialized 
or usual care allied health therapy was based on the choices of pa-
tients and referring physicians. We did not have access to diagnostic 
codes of patients who were treated exclusively by physicians other 
than neurologists (e.g., family physicians, geriatricians), but this in-
volves only a very small minority of Dutch patients with PD. In the 
2012 health insurance claims database, regional data were catego-
rized into 66 regions of the Netherlands with a similar number of 
allied health professionals. Because of an increase in the number of 
allied health professionals between 2012 and 2017, some regions 
were split into smaller subregions. As a result, there were 70 regions 
in the 2017 database. We extracted data on the total population 
of the Netherlands in 2012 and 2017 from Statistics Netherlands 
(Central Agency for Statistics; www.cbs.nl).
We have made summary data on the use of community-based 
physiotherapy, occupational therapy, and speech–language therapy 
in patients with PD publicly available at: https://www.parki nsona 
tlas.nl/.
Specialized care delivery: ParkinsonNet
We defined specialized care deliverers as therapists who participated 
in ParkinsonNet. The remaining therapists, here referred to as generic 
therapists, provided patients receiving usual care and did not receive 
any of the components of the ParkinsonNet intervention. Detailed 
methods of the ParkinsonNet intervention have been published pre-
viously [10,11], and are summarized in Box 1. In short, key elements 
include the specific training of therapists, structuring of the referral 
process (to increase the number of patients with PD seen by special-
ized therapists), and optimization of communication between the 
participating health professionals. To qualify for ParkinsonNet par-
ticipation, therapists had to complete a basic 3-day training program, 
attend follow-up regional interdisciplinary meetings (three times per 
year), attend the ParkinsonNet conference (once biannually), com-
plete annual standardized questionnaires on the quality of care they 
provided, and treat a minimum of five patients with PD each year. 
After the initial introduction of ParkinsonNet, it remained possible 
for additional therapists who previously lacked PD-specific training 
to join the network, provided they could fulfil the requirements for 
ParkinsonNet alliance as outlined above.
Statistical analysis
We determined the number of patients with PD who received spe-
cialized or generic therapy across three disciplines (physiotherapy, 
occupational therapy, and speech–language therapy) between 
2012 and 2017, both at a nationwide and regional level. In the main 
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analysis, we compared the nationwide proportion of patients receiv-
ing specialized care for the calendar years 2012 and 2017 for each 
discipline, using χ2 statistics. For each discipline, we also compared 
the proportion of regions in which at least half (>50%) of patients 
who required therapy were treated by a specialized therapist in the 
years 2012 and 2017. In addition, we assessed the mean ratio of pa-
tients with PD per therapist for the years 2012 and 2017 separately 
for specialized and for generic therapists who treated at least one 
PD patient.
We had some missing data on the level of PD-specific exper-
tise of therapists in 2012, specifically for physiotherapy (13.4%), 
speech–language therapy (12.7%), and occupational therapy (7.5%). 
In 2017, missing data for each discipline were <0.3%. In the main 
analysis, we only used complete data (i.e., in each year we excluded 
patients whose therapist's level of PD-specific expertise was un-
known). Furthermore, we had missing regional data on speech–lan-
guage therapy for four regions in 2012; all other regional data were 
complete. To assess to what extent differentially missing data may 
have affected our observations, we performed separate sensitiv-
ity analyses in which we repeated the main analysis after modeling 
all therapists with an unknown level of PD-specific expertise: (i) in 
2012 as specialized therapists and in 2017 as generic; or (ii) in 2017 
as specialized therapists and in 2012 as generic. We also conducted 
sensitivity analyses on the change in ratio of patients per therapist 
using the same assumptions.
RESULTS
Number of patients with PD
In 2012, the claims database contained 28,913 patients with PD, 
for a total population in the Netherlands of 16,730,000, indicating 
a crude prevalence of PD of 1.8 per 1000 individuals. By 2017, the 
number of patients with PD had risen to 33,382, for a total popu-
lation of 17,082,000, indicating an unadjusted prevalence of PD of 
2.0 per 1000 individuals. This corresponded with a 10% rise in the 
unadjusted prevalence of PD over the study period.
Number of therapists stratified by level of PD 
care expertise
In 2012, there was a total of 25,217 physiotherapists, 3076 speech–
language therapists, and 1373 occupational therapists. By 2017, 
there were 27,643 physiotherapists (+10% compared to 2012), 3975 
speech–language therapists (+29%), and 2090 occupational thera-
pists (+52%). The number of specialized physiotherapists rose dis-
tinctly over the study period (711 in 2012 to 1238 in 2017; +74%), 
as did the number of specialized occupational therapists (247 to 
402; +63%) and specialized speech–language therapists (221 to 377; 
+71%).
Box 1 Key components of the ParkinsonNet approach during the study period
Component Specification
guidelines* • Monodisciplinary—for physiotherapy, speech therapy, occupational therapy, 
nutrition, and nursing home care
• Multidisciplinary—includes a consensus-based model for regional and transmural 
organization of multidisciplinary care and is also available in a patient-friendly format
Preferred referral • Patients and physicians funnel referrals toward ParkinsonNet experts to increase 
their caseload through use of standardized referral forms with referral criteria
Education • Baseline training of participants in treatment guidelines (4 days)
• Learning on the job: increase experience by treating many patients
• Continuous interaction and information exchange between participants through an 
annual national conference, regional interdisciplinary meetings (at least twice a year), 
and participation in web-based national and regional communities
Information technology platform • Informative website (www.Parki nsonN et.nl)
• Healthcare search engine (www.Parki nsonZ orgzo eker.nl)
• Web-based communities for patients and professionals (www.MijnP arkin sonzo rg.nl)
• Electronic health record with decision support
• Telehealth solutions, including video consultations in a safe environment
Selection • Inclusion of motivated healthcare providers only
Commitment • Members agree to work according to treatment guidelines
Transparency about quality of services and 
health outcomes
• Data published in the Parkinson Atlas (www.Parki nsonA tlas.nl)
Patient-centered approach • For example, through use of guidelines for patients, web-based communities for 
patients, personal digital community, and a patient-centered questionnaire (PCQ-PD)
* Evidence-based recommendations and consensus-based statements (www.parki nsonn et.nl/parki nson/behan delri chtli jnen) 
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Number of patients with PD with therapy stratified by 
level of PD-specific expertise
The numbers of patients with PD with physiotherapy, speech–lan-
guage therapy, and occupational therapy, stratified by level of PD-
specific expertise, are shown in Figure 1 for each year between 2012 
and 2017. Between 2012 and 2017, the number of patients with PD 
with any physiotherapist rose from 17,843 in 2012 (62% of all pa-
tients with PD that year) to 22,282 (68%) in 2017. That rise was due 
exclusively to an increase in the number of patients with PD treated 
by a specialized physiotherapist, whereas the number of patients 
with PD treated by a generic physiotherapist or a physiotherapist 
with an unknown level of PD expertise declined (Figure 1). The per-
centage of physiotherapy-requiring patients treated by a special-
ized physiotherapist rose from 36% in 2012 to 62% in 2017 (+26%; 
χ2 = 2460.2; p < 0.001).
The number of patients with any speech–language therapist rose 
from 2171 in 2012 (8% of all patients with PD that year) to 3378 
in 2017 (10%). That rise was exclusively due to an increase in the 
number of patients with PD treated by a specialized speech–lan-
guage therapist, whereas the number of patients with PD treated by 
a generic speech–language therapist or a speech–language therapist 
with an unknown level of PD expertise declined (Figure 1). The per-
centage of patients requiring speech–language therapy treated by 
a specialized speech–language therapist rose from 59% in 2012 to 
85% in 2017 (+26%; χ2 = 445.4; p < 0.001).
The number of patients with any occupational therapist rose 
from 2813 in 2012 (10% of all patients with PD that year) to 5939 in 
2017 (18%). That rise was largely due to an increase in the number 
of patients with PD treated by a specialized occupational therapist. 
The number of patients with PD treated by a generic occupational 
therapist also increased, albeit less distinctly, whereas the number of 
patients with PD treated by a generic occupational therapist with an 
unknown level of PD expertise declined (Figure 1). The percentage 
of patients requiring occupational therapy treated by a specialized 
occupational therapist rose from 61% in 2012 to 77% in 2017 (+16%; 
χ2 = 231.6; p < 0.001).
In sensitivity analyses, our observations remained robust under sev-
eral different assumptions on the level of PD-specific expertise of thera-
pists of whom that level was unknown (Supplementary Material 1).
Regional distribution of specialized care delivery
Nationwide claims data were categorized into 66 regions of the 
Netherlands in 2012, whereas data were categorized into 70 regions 
in 2017. In 2012, in only 5 (8%) of 66 regions were the majority of 
physiotherapy-requiring patients with PD treated by a specialized 
physiotherapist. By 2017, the majority of physiotherapy-requiring 
patients with PD was treated by a specialized physiotherapist in 63 
(90%) of 70 regions. The number and percentage of regions in which 
the majority of therapy-requiring patients with PD were treated by 
a specialized speech–language therapist (45 [73%] to 68 [97%]) and 
occupational therapist (49 [74%] to 68 [97%]) also rose substantially. 
In Figure 2, the regional distribution of therapy-requiring patients 
with PD with a specialized therapist in 2012 and in 2017 is further 
specified.
Ratio of patients per therapist
As illustrated in Figure 3, the mean ratio of patients per generic physi-
otherapist was very low and even declined somewhat throughout 
the study period (1.1 in 2012 and 1.0 in 2017, corresponding with a 
9% decline). The mean ratio of patients per generic speech–language 
therapist (1.4 in 2012 and 1.2 in 2017; −19%) and generic occupational 
F I G U R E  1  Trends in the number of patients with a physiotherapist, occupational therapist, or speech–language therapist, stratified by 
level of Parkinson's disease (PD)–specific expertise. These graphs illustrate the number of patients with a physiotherapist, occupational 
therapist, or speech–language therapist in 2012 and 2017, stratified by level of PD-specific expertise. Exact numbers are provided below 
the graphs. Level of PD-specific expertise of the therapists was classified as either specialized or generic. For each discipline, the difference 
in the proportion of patients with PD with a specialized therapist between 2012 and 2017 was statistically significant (p < 0.001).
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therapist (2.3 in 2012 and 2.0 in 2017; −16%) was also very low and 
declined further. By contrast, the mean ratio of patients per special-
ized physiotherapist (8.4 in 2012 and 11.4 in 2017; +35%), special-
ized speech–language therapist (5.5 in 2012 and 7.9 in 2017; +42%) 
and specialized occupational therapist (7.3 in 2012 and 12.0 in 2017; 
+65%) increased substantially throughout the study period.
In sensitivity analyses, the increase in ratio of patients per spe-
cialized speech–language therapist and ratio of patients per occupa-
tional therapist remained robust under several different assumptions 
on the level of PD care expertise of therapists of whom that level was 
unknown (Supplementary Material 2). For generic occupational ther-
apists, the ratio of patients per therapist would have declined in each 
scenario. For the ratio of patients per specialized physiotherapist, 
generic physiotherapist, or generic speech–language therapist the 
direction of change would have varied under different assumptions.
DISCUSSION
Through implementation of the ParkinsonNet approach, coverage 
of cost-effective community-based specialized care delivery to pa-
tients with PD in the Netherlands improved considerably between 
2012 and 2017. Furthermore, during this study period, we observed 
a substantial growth in the number and proportion of patients per 
specialized therapist, suggesting a greater concentration of PD care 
among specialized providers. Clinical trials had shown that special-
ized therapists achieve better outcomes than generically trained 
therapists, partially because of their greater case load [3,4,8,9]. As 
the volume shifts described here took place after completion of 
these clinical trials, it is conceivable that the long-term effectiveness 
of specialized care delivery may be even larger than previously esti-
mated. Taken together, we believe that this successful expansion of 
a cost-effective care approach to a nationwide scale might serve as 
an example to improve care elsewhere, not only for PD but also for 
other chronic conditions.
Before further interpreting the results, we will address several 
limitations of this study. First, because PD case detection depended 
on diagnostic codes of neurological clinics, we could not include 
patients who never visited any hospital or who during the 6-year 
study period were treated exclusively by other specialists (e.g., 
geriatricians). Patients who never visited a hospital are generally 
more care-evasive, and specialized community-based care may not 
have reached these patients. However, this subgroup is likely small, 
as the prevalence of PD in this study (2 per 1000 individuals) was 
similar to the prevalence of PD in population-based studies with 
in-person examinations [12]. Second, we had no access to data on 
F I G U R E  2  Regional distribution of therapy-requiring patients with a specialized therapist in 2012 and 2017. This graph illustrates the 
percentage of Parkinson's disease patients with community-based physiotherapy, occupational therapy, and speech–language therapy who 
were treated by a specialized therapist. Of note, claims data were categorized into 66 regions of the Netherlands in 2012, whereas data were 
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allied health interventions delivered in hospitals or nursing homes. 
Third, because PD case detection depended on diagnostic codes, we 
probably included some patients who actually had a form of atyp-
ical parkinsonism. However, it is unlikely that this misclassification 
differentially affected specialized or generic allied health therapy. 
Fourth, the level of PD-specific expertise was unknown for some 
therapists, especially during the first few years of follow-up. We 
performed several sensitivity analyses to assess to what extent our 
observations would have been different in several hypothetical sce-
narios with respect to the level of PD-specific expertise of those 
therapists. For each scenario, the rise in number of patients treated 
by a specialized therapist between 2012 and 2017 remained robust 
across each discipline. Despite these limitations, a unique strength 
of this study was that we could leverage nationwide data on the use 
of community-based physiotherapy, speech–language therapy, and 
occupational therapy over a 6-year period, allowing us to rigorously 
assess temporal trends in the coverage of specialized care delivery 
on an unprecedented scale.
In the 2012 to 2017 interval, several other interventions raised 
greater awareness of the benefits of specialized care among people 
with PD as well as among healthcare professionals, ranging from vir-
tual house calls to patient-centered education on management of 
daily life issues [13,14]. A distinguishing feature of the ParkinsonNet 
intervention was the focus on specialized training and empow-
erment of allied health therapists who work in the community. 
Importantly, in this study, we observed a stark contrast in tempo-
ral trends between allied health professionals who received specific 
training through the ParkinsonNet approach and those who did 
not. Although the number of patients receiving care by allied health 
professionals participating in ParkinsonNet increased substantially 
between 2012 and 2017, the number of patients seen by the other 
nonparticipating allied health professionals did not change mean-
ingfully. Furthermore, the case load per therapist only increased for 
allied health professionals participating in the ParkinsonNet inter-
vention, and the proportion of regions in which allied health ther-
apy was predominantly delivered by professionals participating in 
the ParkinsonNet intervention rose substantially during the study 
period. These findings make it unlikely that the changes in referral 
patterns could be explained by generic trends toward greater infor-
mation provision in the Netherlands. We previously demonstrated 
that healthcare costs are lower in ParkinsonNet clusters compared 
with usual-care clusters [3]. We also showed that specialized phys-
iotherapy as delivered through ParkinsonNet is associated with 
fewer PD-related complications in real-world practice [9], and that 
occupational therapy improves self-perceived performance in daily 
activities by patients with PD [4], with lower costs for caregivers 
[8]. However, it remained unclear to what extent such specialized 
care delivery, as demonstrated in clinical trials, could subsequently 
be extended into a sustainable implementation within everyday clin-
ical practice. Here, we observed that the number of patients with 
PD with any form of physiotherapy, speech–language therapy, or 
occupational therapy increased substantially between 2012 and 
2017. These increases could not be explained by an increase in un-
adjusted prevalence of PD during the study period (10% in 6 years), 
and hence more likely reflects the growing recognition that optimal 
management of PD requires a multidisciplinary approach [15,16]. 
For physiotherapy and speech–language therapy, the increase was 
exclusively due to a growth in the number of patients treated by 
a specialized therapist, whereas the number of patients with a ge-
neric therapist declined. For occupational therapy, the number of 
patients increased for both specialized and generic therapists, but 
the increase was far more distinct for specialized therapists.
The number of community-based specialized therapists in-
creased substantially during the study period, due to the nation-
wide ParkinsonNet training programs. Furthermore, when looking 
at regional distribution of specialized care delivery, we observed 
that the proportion of patients receiving specialized therapists in 
regions that were previously poorly covered increased substantially 
during the study period. In fact, the percentage of regions in which 
the majority of physiotherapy-requiring patients were treated by a 
specialized physiotherapist rose from 8% in 2012 to 90% in 2017, 
whereas specialized speech–language therapy and occupational 
therapy was provided to the majority of therapy-requiring patients 
in almost all (97%) regions by 2017. The successful implementation 
of the ParkinsonNet intervention was likely driven by several factors 
[17]. First, the ParkinsonNet intervention was experienced as a wel-
come intervention by the participating allied health professionals, 
who now felt more empowered to treat this complex neurological 
condition, and also by the patients, who now were able to obtain 
ready access to highly specialized professionals who understood the 
intricacies of their condition. An important success factor was the 
development of guidelines, which, in the absence of more convinc-
ing scientific evidence in the early days of the network implementa-
tion, were initially largely determined by practice-based evidence. 
These guidelines served as educational materials for the baseline 
training of all participating professionals, helped to reduce unwanted 
variations in care between professionals, and served as a basis for 
the intervention arm in subsequent randomized clinical trials that 
F I G U R E  3  The ratio of Parkinson's disease patients per therapist in 2012 and 2017, stratified by level of Parkinson's disease–specific 
expertise. Mean ratio of Parkinson's disease patients per therapist by year, stratified for generic and specialized therapists
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were performed to gather further evidence. These trials were a 
further important success factor, as it helped to provide a robust 
evidence base that demonstrated the cost-effectiveness of the net-
work approach. Another crucial determinant was the commitment of 
the neurologists and PD nurse specialists to preferentially refer pa-
tients to the specialized allied health therapists working in the com-
munity, allowing them to now substantially increase their caseload 
and thereby redeem the time investment of their baseline training. 
The supporting Information technology backbone also helped with 
the successful limitation of ParkinsonNet in various ways. The web-
based healthcare finder further facilitated the referral process and 
concentration of care among the trained experts, whereas the use 
of web-based communities allowed for easy communication about 
complex cases and new research findings. The fact that education 
did not stop after the baseline training program was also felt to be 
helpful: all participating professionals meet three times a year during 
regional events and meet at least once every 2 years during a na-
tional congress, which serves both to educate and inspire the par-
ticipants. However, implementation of the network also met with a 
number of challenges. Perhaps the greatest difficulty was the disap-
pointment among healthcare professionals who were not allowed to 
enter the network, because inclusion of too many participants would 
conflict with the ParkinsonNet aim to concentrate care among a lim-
ited number of highly trained professionals. As demonstrated here, 
nonparticipants experienced a gradual reduction in number of per-
sons with PD in their practices, which by some was experienced as a 
loss of their professional joy. The second major challenge related to 
the financial reimbursement of this innovative healthcare approach. 
Just like a hospital or another type of institutionalized care, net-
works require a certain amount of overhead, for example, to oversee 
the training programs, to updated guidelines, and to maintain the 
information technology backbone. The insurance companies ini-
tially found it difficult to identify the proper means to reimburse the 
network overhead, because their systems were traditionally aimed 
at funding institutions rather than integrated networks. This latter 
challenge has meanwhile been overcome in the Netherlands, where 
the insurance companies now collectively reimburse the overhead 
of the nationwide ParkinsonNet network, which clearly outweighs 
the net cost savings that are achieved annually [18].
Taken together, the success factors outweighed the chal-
lenges—most of these have meanwhile been overcome—and this 
likely explains why implementation of the ParkinsonNet approach 
was successfully introduced at a nationwide scale as a cost-effec-
tive intervention in the Netherlands [3,4]. In a broader context, it is 
noteworthy that the ParkinsonNet approach, which was developed 
in the public insurance-based healthcare system of the Netherlands, 
has recently been successfully introduced in healthcare systems that 
have a different infrastructure (e.g., Kaiser Permanente, an account-
able care organization in California) [19]. Future studies are war-
ranted to assess whether wide-scale coverage of specialized allied 
health services can also be achieved in those healthcare systems, as 
well as its possible implications for cost savings.
In conclusion, coverage of cost-effective specialized care de-
livery to patients with PD in the Netherlands improved consider-
ably between 2012 and 2017 following implementation of the 
ParkinsonNet approach. The successful implementation of this spe-
cialized care approach on a nationwide scale can serve as a template 
to improve care for patients with PD or other chronic conditions 
elsewhere.
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